A surgeon with the Breast Health Center at Women & Infants Hospital of Rhode Island, a Care New England hospital, is among the first in New England to adopt an innovative new device that improves the treatment of breast cancer by more precisely targeting radiation treatment and providing for better follow-up exams.
David Edmonson, MD, has helped pioneer the use of the BioZorb™ marker, a three-dimensional device that is placed in the breast during a lumpectomy, the conservation surgery performed to remove only the cancer and not the entire breast. The BioZorb marker is the first device that identifies in a fixed, 3D manner where the tumor was removed, helping the radiation oncologist more reliably determine where to aim the radiation in follow-up treatments.
The marker consists of a spiral made of a bioabsorbable material that holds six titanium clips. The spiral slowly dissolves in the body over the course of a year or more, leaving the tiny marker clips in place so the surgical site can be viewed for long-term monitoring.
"We've now used the marker with more than 100 patients, and we've found it is useful with a wide variety of patients," said Dr. Edmonson. "The marker has also allowed some women who would not previously have been candidates for breast conservation treatment to have a lumpectomy. This device helps us achieve better cosmetic outcomes and improves our communication with the radiation oncologist about the specific area of the breast to target with follow-up radiation."
Breast cancer can be treated surgically by mastectomy (breast removal) or by lumpectomy. With lumpectomy, a small amount of tissue containing the tumor is removed. In addition to the surgery, radiation treatment is typically added to "clean up" any microscopic cancer cells that might remain behind in the breast. Using traditional methods, the full course of radiation treatment was directed at the entire breast. While this approach is proven to reduce the risk of cancer recurrence, it can also expose healthy tissue to radiation.
"Before the Biozorb device was available, we had to rely on techniques that gave us an inexact idea of where to aim the radiation," said Darlene Gabeau, MD, PhD, medical director at 21st Century Oncology, the radiation therapy provider of choice for Care New England. Dr. Gabeau treats many of Dr. Edmonson's patients after surgery. "The new device is sutured right to the involved site providing a three-dimensional representation of the tumor bed allowing more precise treatments."
Among the patients who have benefited from the BioZorb device's availability at Women & Infants is Ann Hall, 59, of Carolina, RI, whose breast cancer was detected earlier this year by mammogram and a biopsy.
Hall went to Women & Infants for treatment, she said, because, "I felt they had the best technology to treat me in the most sophisticated way possible. Dr. Edmonson told me the BioZorb would help them direct the radiation right where they needed to, so there would be less damage to surrounding tissue and organs. That sounded good to me!"
In April of this year, Dr. Edmonson performed Hall's lumpectomy to remove her tumor and placed the marker during surgery. Hall said she is gratified the marker enabled her radiation oncologist to zero in on the tumor area and minimize any damage to healthy tissue. She is also pleased with the cosmetic results.
"The device kind of filled in the gap where the tumor was, just as Dr. Edmonson said it would," she said. "I think that really does help with the cosmetic outcome. Both my oncologist and radiologist have complemented me on Dr. Edmonson's work."
Explaining how the device helps with the cosmetic aspects of the healing process, Dr. Edmonson said, "The same spiral that helps us mark the tumor site in three dimensions serves as a structure for new tissue to form in and around. So it helps new tissue essentially replace the tissue we took out. Potentially, this helps us achieve a better cosmetic result."
###
Dr. Edmonson is a surgeon in the Breast Health Center, part of the Program in Women's Oncology at Women & Infants. He is also medical director of the hospital's Lymphedema Program and the physician liaison for its Cancer Committee. For more information about the Breast Health Center at Women & Infants, go to womenandinfants.org/breasthealth or call (401) 453-7540.
About Women & Infants Hospital of Rhode Island
Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation's leading specialty hospitals for women and newborns. A major teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women's medicine, Women & Infants is the 12th largest stand-alone obstetrical service in the country with approximately 8,400 deliveries per year. A Designated Baby-Friendly® USA hospital, U.S. News & World Report 2014-15 Best Children's Hospital in Neonatology and a 2014 Leapfrog Top Hospital, in 2009 Women & Infants opened what was at the time the country's largest, single-family room neonatal intensive care unit.
Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation's only mother-baby perinatal psychiatric partial hospital, as well as the nation's only fellowship program in obstetric medicine.
Women & Infants has been designated as a Breast Center of Excellence by the American College of Radiography; a Center of Excellence in Minimally Invasive Gynecology; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health (NIH); and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute's Gynecologic Oncology Group and the NICHD Pelvic Floor Disorders Network.